focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.15
Bid: 6.80
Ask: 7.50
Change: 0.00 (0.00%)
Spread: 0.70 (10.294%)
Open: 7.15
High: 7.15
Low: 7.15
Prev. Close: 7.15
KMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kromek awarded further $748K contract by DARPA

22 Feb 2016 07:00

RNS Number : 6708P
Kromek Group PLC
22 February 2016
 

 

Approved for Public Release, Distribution Unlimited

 

22 February 2016

 

Kromek Group plc

("Kromek" or the "Company")

 

Kromek awarded further $748K contract by DARPA

US defence agency modifies contract to add $0.75m for the retrofit of 200 legacy detectors

 

Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce that it has been awarded a modification to its existing contract with the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, for the design, development and supply of electronics modules to provide a universal interface, capable of processing data from either SiPM arrays or from standard photomultipliers (PMTs), and to help retrofit and test 200 legacy detectors with new base electronics modules with both wired and wireless connection capability. The contract modification, to be delivered by 30 April 2017, is worth up to an additional c. $0.75m. From August 2014 to date, Kromek has been awarded a total of $5.37m in contracted revenues under the SIGMA programme with DARPA. Today, the Company also announced the award of a separate sole source contract, worth approximately $6.0m, to supply its D3S modules and chargers to DARPA.

 

The extension to the existing contract is for the utilisation of the technologies and building blocks, developed by Kromek for the D3S product for DARPA, in legacy gamma scintillation detectors. The intention is to ascertain if these legacy detectors can be retrofitted with updated technology so that they can be used in either mobile or vehicle mounted systems. The primary purpose of the modified electronics module is to enable DARPA to utilise a large number of these legacy scintillation detectors that are currently not being used. The secondary goal of the development is to establish a method for implementing a Silicon Photomultiplier-based interface to these scintillation detectors to increase robustness, compactness and ability to withstand high temperature, shock and vibration - all at a lower cost.

 

Arnab Basu, Chief Executive Officer, said: "The detector technologies we have developed have significant potential for various applications in a number of other major U.S. Government agency programmes requiring similar capability. We expect our work with DARPA will enable us to continue to provide innovative solutions to them and others seeking to protect against acts of terrorism."

 

The programme with DARPA, which commenced in August 2014, was to develop an advanced personal detection system for gamma and neutron radiation that can be combined with other such systems to form large networks that can provide information on radiation signatures over an extended area. As stated in the announcement on 5 October 2015, DARPA issued a Sole Source Notice stating that it intended to award a sole source contract to Kromek to supply D3S, the spectroscopic personal radiation detectors (SPRDs) in support of DARPA's SIGMA programme. The Directors believe that it is the success of this programme that has led to the extension of the contract being announced today.

 

Enquiries

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

+44 (0)1740 626 060

Cenkos Securities plc

Bobbie Hilliam (NOMAD)

Julian Morse, Michael Johnson (Sales)

+44 (0)20 7397 8900

Luther Pendragon Ltd

Harry Chathli, Claire Norbury, Alexis Gore

+44 (0)20 7618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology, Kromek designs develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over a hundred full time employees across its global operations. Further information on Kromek Group is available at www.kromek.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTAKDDDBBKBCBB
Date   Source Headline
13th Jan 20217:01 amRNSFunding to advance Bio-Threat Detection solution
13th Jan 20217:00 amRNSInterim Results
7th Jan 202111:05 amRNSSecond Price Monitoring Extn
7th Jan 202111:01 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSDirectorate Changes
14th Dec 202012:45 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSNotice of Results
8th Dec 20207:00 amRNSContract extensions for D3S products
3rd Dec 20207:00 amRNSKromek launches the D5 RIID radiation detector
2nd Nov 20207:00 amRNSKromek wins new sector-leading global OEM customer
2nd Nov 20207:00 amRNSResult of AGM
29th Oct 20207:00 amRNSDirectorate Change
14th Oct 20207:00 amRNSKromek CZT technology to improve cancer surgery
9th Oct 20204:41 pmRNSSecond Price Monitoring Extn
9th Oct 20204:36 pmRNSPrice Monitoring Extension
8th Oct 20205:28 pmRNSHolding(s) in Company
8th Oct 20204:44 pmRNSNotice of AGM and Publication of Annual Report
8th Oct 202012:58 pmRNSDirector Share Purchase
8th Oct 20207:00 amRNSAppointment of Non-executive Director
7th Oct 202011:13 amRNSDirector Share Purchase
7th Oct 202011:00 amRNSPrice Monitoring Extension
7th Oct 20207:00 amRNSFinal Results
28th Sep 20203:00 pmRNSHolding(s) in Company
17th Sep 20201:53 pmRNSHolding(s) in Company
27th May 20207:00 amRNSKromek awarded new DARPA bio-surveillance contract
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20209:05 amRNSSecond Price Monitoring Extn
1st May 20209:00 amRNSPrice Monitoring Extension
1st May 20207:00 amRNSFull Year Trading Update and Response to COVID-19
27th Apr 202010:57 amRNSHolding(s) in Company
21st Apr 20207:00 amRNSKromek receives Queen’s Award
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSKromek to produce ventilators to fight COVID-19
20th Mar 202010:52 amRNSHolding(s) in Company
18th Feb 20204:15 pmRNSHolding(s) in Company
27th Jan 202012:42 pmRNSSite visit by International Trade Secretary
9th Jan 20204:55 pmRNSHolding(s) in Company
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20197:00 amRNSDirector Share Purchase
12th Dec 20197:00 amRNSDirector Share Purchases
11th Dec 20197:00 amRNSInterim Results
5th Dec 20197:00 amRNSNotice of Results
4th Dec 20195:25 pmRNSHolding(s) in Company
26th Sep 20191:14 pmRNSResult of AGM
24th Sep 20197:00 amRNSKromek awarded two contracts for D3S products
30th Aug 20191:50 pmRNSNotice of AGM and Publication of Annual Report
1st Jul 20197:00 amRNSNew contracts for D3S in UK, US and Europe

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.